Debate Continues on When Best to Use Mesothelioma ChemotherapyTreatment & Doctors
Asbestos.com is the nation’s most trusted mesothelioma resource
The Mesothelioma Center at Asbestos.com has provided patients and their loved ones the most updated and reliable information on mesothelioma and asbestos exposure since 2006.
Our team of Patient Advocates includes a medical doctor, a registered nurse, health services administrators, veterans, VA-accredited Claims Agents, an oncology patient navigator and hospice care expert. Their combined expertise means we help any mesothelioma patient or loved one through every step of their cancer journey.
More than 30 contributors, including mesothelioma doctors, survivors, health care professionals and other experts, have peer-reviewed our website and written unique research-driven articles to ensure you get the highest-quality medical and health information.
About The Mesothelioma Center at Asbestos.com
- Assisting mesothelioma patients and their loved ones since 2006.
- Helps more than 50% of mesothelioma patients diagnosed annually in the U.S.
- A+ rating from the Better Business Bureau.
- 5-star reviewed mesothelioma and support organization.
"My family has only the highest compliment for the assistance and support that we received from The Mesothelioma Center. This is a staff of compassionate and knowledgeable individuals who respect what your family is experiencing and who go the extra mile to make an unfortunate diagnosis less stressful. Information and assistance were provided by The Mesothelioma Center at no cost to our family."LashawnMesothelioma patient’s daughter
How to Cite Asbestos.com’s Article
Povtak, T. (2020, October 16). Debate Continues on When Best to Use Mesothelioma Chemotherapy. Asbestos.com. Retrieved February 6, 2023, from https://www.asbestos.com/news/2019/01/03/chemotherapy-mesothelioma-debate/
Povtak, Tim. "Debate Continues on When Best to Use Mesothelioma Chemotherapy." Asbestos.com, 16 Oct 2020, https://www.asbestos.com/news/2019/01/03/chemotherapy-mesothelioma-debate/.
Povtak, Tim. "Debate Continues on When Best to Use Mesothelioma Chemotherapy." Asbestos.com. Last modified October 16, 2020. https://www.asbestos.com/news/2019/01/03/chemotherapy-mesothelioma-debate/.
Oncologists have debated for years whether standard chemotherapy delivered before or after aggressive surgery is more effective in treating patients with mesothelioma.
The debate isn’t ending anytime soon.
The first randomized phase II clinical trial examining the issue isn’t scheduled to conclude until April 2020.
Surgical patients often are faced with this dilemma when they contemplate second opinions and decide where to receive specialized treatment.
“It often comes down to an institution’s preference, or a surgeon’s preference, or the medical oncologist’s preference, but not necessarily knowing for sure which is best for the patient,” Dr. Charles Simone, University of Maryland Comprehensive Cancer Center radiation oncologist, told The Mesothelioma Center at Asbestos.com. “So we’ve tried to answer the question for the first time.”
Past Results Not Definitive
Simone is the lead author of a recent, retrospective study on the topic that analyzed almost 400 surgical patients from the National Cancer Database.
The study could be a precursor to the ongoing clinical trial in Europe.
All had the epithelioid or biphasic subtype of pleural mesothelioma.
Half completed chemotherapy before surgery. The other half did chemotherapy treatment after surgery.
Research found no definitive advantage — either way — on when best to use chemotherapy.
The Journal of Thoracic and Cardiovascular Surgery published the study, which included these findings:
Induction Chemotherapy Followed by Surgical Resection
20.9-month median overall survival
7-day postoperative hospitalization
3.3 percent 30-day mortality
Resection Followed by Postoperative Chemotherapy
21.7-month median overall survival
6-day postoperative hospitalization
0 percent 30-day mortality
“There are pros and cons on both sides,” Simone said. “In Europe, they still like to do the chemotherapy first. Here in the United States, there is more of the mentality that if you think surgery is the best way to achieve long-term survival, why delay it? Fewer centers now are doing chemotherapy first in this country.”
Advantages and Disadvantages
According to the study, the potential advantages and disadvantages of chemotherapy before surgery include:
A more optimal full-dose delivery of chemotherapy — which could lead to tumor reduction or complete response — and a better chance at total tumor debulking.
A better idea if aggressive surgery will actually help. Tumor progression during chemotherapy usually means a poor prognosis, which would allow patients to bypass a debilitating surgery that will do more harm than good.
Difficult side effects from chemotherapy could delay or preclude surgery or increase surgical complications.
Conversely, having surgery first could limit a patient’s ability to undergo full multidisciplinary treatment, potentially eliminating the chance to undergo full-dose chemotherapy.
“This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.”
European Trial May Be More Definitive
The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study.
The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed and cisplatin chemotherapy.
A second group will receive the same chemotherapy combination before the P/D procedure.
“The primary objective of the study is to investigate the feasibility of immediate P/D, followed by chemotherapy, or deferred P/D after chemotherapy in patients with early stage malignant pleural mesothelioma,” the clinical trial authors wrote.
The trial started in 2016, hoping to determine if one method is better than the other.
Researchers plan to use the more advantageous procedure in a comparative study with either the extrapleural pneumonectomy surgery or a no-surgery control arm.